- Home
- BCG vs CVM Comparison
BCG vs CVM Comparison
Compare BCG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | CVM |
|---|---|---|
| Founded | 2016 | 1983 |
| Country | United States | United States |
| Employees | 150 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 21.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | BCG | CVM |
|---|---|---|
| Price | $1.54 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.7K | ★ 414.8K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.36 | $0.89 |
| 52 Week High | $3.44 | $13.48 |
Technical Indicators
Market Signals| Indicator | BCG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 50.47 |
| Support Level | $1.50 | $0.95 |
| Resistance Level | $1.68 | $1.59 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 20.01 | 70.04 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.